Major Korro Bio (KRRO) holder adds shares and pre-funded warrants in March 10 Form 4

Rhea-AI Filing Summary

Korro Bio, Inc. reported that investment entities associated with Rick Yang made significant indirect open-market purchases of its securities. On March 10, 2026, New Enterprise Associates 17, L.P. acquired 242,945 Pre-Funded Warrants at $11.1090 per warrant and 207,100 shares of Common Stock at $11.1100 per share under a Subscription Agreement dated March 9, 2026. Following these transactions, NEA 17 indirectly holds 1,297,893 shares of Common Stock and the Pre-Funded Warrants, while the Reporting Person disclaims beneficial ownership where there is no pecuniary interest. The Pre-Funded Warrants are exercisable at any time, subject to a 9.99% ownership cap that can be adjusted up to 19.99% with 61 days’ prior notice.

Insights

Equity ownership and insider-transactions analyst

Large fund linked to a 10% holder added Korro Bio exposure via stock and pre-funded warrants.

Entities affiliated with New Enterprise Associates 17, L.P. bought both Common Stock and Pre-Funded Warrants in Korro Bio on March 10, 2026. The transactions total 450,045 securities across 242,945 warrants and 207,100 shares, at prices just above $11.11.

The reporting person is a manager of the NEA entities and disclaims beneficial ownership where there is no pecuniary interest, so these are best viewed as fund-level, not personal, purchases. After the trades, NEA 17 holds 1,297,893 Common shares plus the newly acquired warrants.

The Pre-Funded Warrants are exercisable immediately but include a 9.99% Beneficial Ownership Limitation, adjustable up to 19.99% with 61 days’ notice. This limits how many shares can be issued at once, so actual dilution and ownership concentration depend on how NEA 17 chooses to exercise over time.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yang Rick

(Last) (First) (Middle)

2855 SAND HILL ROAD

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		P(1)		207,100	A	$11.11	1,297,893	I	See Note 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Pre-Funded Warrants	$0.001	03/10/2026		P(1)		242,945		(3)	(3)	Common Stock	242,945	$11.109	242,945	I	See Note 2(2)

Explanation of Responses:

1. Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026.

2. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

3. The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.

	/s/ Zachary Bambach, attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the NEA-affiliated holder buy in Korro Bio (KRRO) on March 10, 2026?

An entity affiliated with New Enterprise Associates 17, L.P. bought 242,945 Pre-Funded Warrants at $11.1090 and 207,100 shares of Common Stock at $11.1100 per share, all in indirect open-market purchase transactions.

How many Korro Bio (KRRO) shares does NEA 17 hold after these transactions?

After the March 10, 2026 trades, NEA 17 is reported as indirectly holding 1,297,893 shares of Korro Bio Common Stock. It also holds 242,945 Pre-Funded Warrants that are exercisable into an equal number of Common shares, subject to ownership limits.

What are the terms of the Korro Bio (KRRO) Pre-Funded Warrants purchased by NEA 17?

The Pre-Funded Warrants have an exercise price of $0.0010 per share and are exercisable at any time after issuance. However, they cannot be exercised above a 9.99% ownership cap, which can be raised up to 19.99% with 61 days’ notice.

Was Rick Yang personally buying Korro Bio (KRRO) shares in this Form 4?

The transactions are attributed to New Enterprise Associates 17, L.P., with holdings reported as indirect. Rick Yang is a manager of related general partners and disclaims beneficial ownership of securities in which he has no pecuniary interest under Section 16.

How were the Korro Bio (KRRO) securities acquired by the NEA entity documented?

The Form 4 notes that the securities were acquired from Korro Bio on March 10, 2026 under a Subscription Agreement dated March 9, 2026. The filing characterizes the transactions as open-market or private purchases for both the stock and the Pre-Funded Warrants.

Why is there a 9.99% ownership limit on the Korro Bio (KRRO) Pre-Funded Warrants?

The Pre-Funded Warrants include a Beneficial Ownership Limitation that prevents exercises above 9.99% of outstanding Common Stock. This cap, adjustable up to 19.99% with 61 days’ notice, controls post-exercise ownership concentration from a single holder and related parties.